Mechanisms underlying type I diabetes

Drug Discovery Today: Disease Mechanisms

Volumn 1, Issue 3, 2004, Pages 321-327

  Bresson, Damien ^a   Von Herrath, Matthias ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GLUTAMATE DECARBOXYLASE 65; GLUTEN; INSULIN; MONOCLONAL ANTIBODY CD3; RECOMBINANT ENZYME;

AUTOIMMUNITY; B LYMPHOCYTE; CELL DESTRUCTION; CEREAL; CLINICAL TRIAL; COXSACKIE VIRUS INFECTION; DISEASE MODEL; ENVIRONMENTAL FACTOR; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIFE EVENT; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PANCREAS ISLET BETA CELL; REVIEW; T LYMPHOCYTE;

EID: 23744445819     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2004.11.015     Document Type: Review

References (46)

1. Merriman, T.R. et al. (1995) Genetics of autoimmune disease. Curr. Opin. Immunol. 7, 786-792
2. Akerblom, H.K. et al. (2002) Environmental factors in the etiology of type 1 diabetes. Am. J. Med. Genet. 115, 18-29
3. Risch, N. (1989) Genetics of IDDM: evidence for complex inheritance with HLA. Genet. Epidemiol. 6, 143-148
4. Devendra, D. et al. (2004) Type 1 diabetes: recent developments. Br. Med. J. 328, 750-754
5. Devendra, D. et al. (2003) Immunologic endocrine disorders. J. Allergy Clin. Immunol. 111 (2 Suppl.), S624-S636
6. Vaidya, B. et al. (2004) The emerging role of the CTLA-4 gene in autoimmune endocrinopathies. Eur. J. Endocrinol. 150, 619-626
7. Bassuny, W.M. et al. (2003) A functional polymorphism in the promoter/enhancer region of the FOXP3/Scurfin gene associated with type 1 diabetes. Immunogenetics 55, 149-156
8. Ramsdell, F. (2003) Foxp3 and natural regulatory T cells: key to a cell lineage? Immunity 19, 165-168
9. Fontenot, J.D. et al. (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4, 330-336
10. Salvetti, M. et al. (2000) Twins: mirrors of the immune system. Immunol. Today 21, 342-347
11. Zinkernagel, R.M. (2002) Antiinfection immunity and autoimmunity. Ann. N. Y. Acad. Sci. 958, 3-6
12. Christen, U. et al. (2004) Induction, acceleration or prevention of autoimmunity by molecular mimicry. Mol. Immunol. 40, 1113-1120
13. Green, J. et al. (2004) Coxsackie B virus serology and type 1 diabetes mellitus: a systematic review of published case-control studies. Diabet. Med 21, 507-514
14. McIntosh, E.D. et al. (1992) A fifty-year follow-up of congenital rubella. Lancet 340, 414-415
15. Hviid, A. et al. (2004) Childhood vaccination and type 1 diabetes. N. Engl. J. Med. 350, 1398-1404
16. Viskari, H. et al. (2003) Humoral beta-cell autoimmunity is rare in patients with the congenital rubella syndrome. Clin. Exp. Immunol. 133, 378-383
17. Tracy, S. et al. (2002) Toward testing the hypothesis that group B coxsackieviruses (CVB) trigger insulin-dependent diabetes: inoculating nonobese diabetic mice with CVB markedly lowers diabetes incidence. J. Virol. 76, 12097-12111
18. Nagayama, Y. et al. (2004) Graves' hyperthyroidism and the hygiene hypothesis in a mouse model. Endocrinology 145, 5075-5079
19. Hayashi, T. et al. (2004) Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J. Clin. Invest. 114, 270-279
20. Fossati, G. et al. (1999) Triggering a second T cell receptor on diabetogenic T cells can prevent induction of diabetes. J. Exp. Med. 190, 577-583
21. Frigerio, S. et al. (2002) Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat. Med. 8, 1414-1420
22. Christen, U. et al. (2003) Among CXCR3 chemokines, IFN-gamma-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease. J. Immunol. 171, 6838-6845
23. Christen, U. et al. (2004) Cure of prediabetic mice by viral infections involves lymphocyte recruitment along an IP-10 gradient. J. Clin. Invest. 113, 74-84
24. Green, D.R. et al. (2001) The role of Fas ligand in immune privilege. Nat. Rev. Mol. Cell. Biol. 2, 917-924
25. Hsu, P.N. et al. (2001) Expression of human Fas ligand on mouse beta islet cells does not induce insulitis but is insufficient to confer immune privilege for islet grafts. J. Biomed. Sci. 8, 262-269
26. Kang, S.M. et al. (1997) Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3, 738-743
27. Christen, U. et al. (2004) Virally induced inflammation triggers fratricide of Fas-ligand-expressing beta-cells. Diabetes 53, 591-596
28. Kagi, D. et al. (1997) Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J. Exp. Med. 186, 989-997
29. Kagi, D. et al. (1996) Development of insulitis without diabetes in transgenic mice lacking perforin-dependent cytotoxicity. J. Exp. Med. 183, 2143-2152
30. Seewaldt, S. et al. (2000) Virus-induced autoimmune diabetes: most beta-cells die through inflammatory cytokines and not perforin from autoreactive (anti-viral) cytotoxic T-lymphocytes. Diabetes 49, 1801-1809
31. Suk, K. et al. (2001) IFN-gamma/TNF-alpha synergism as the final effector in autoimmune diabetes: a key role for STAT1/IFN regulatory factor-1 pathway in pancreatic beta cell death. J. Immunol. 166, 4481-4489
32. Greeley, S.A. et al. (2002) Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice. Nat. Med. 8, 399-402
33. Noorchashm, H. et al. (1999) I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice. J. Immunol. 163, 743-750
34. Martin, S. et al. (2001) Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N. Engl. J. Med. 345, 1036-1040
35. Koczwara, K. et al. (2004) Transmission of maternal islet antibodies and risk of autoimmune diabetes in offspring of mothers with type 1 diabetes. Diabetes 53, 1-4
36. Notkins, A.L. (2002) Immunologic and genetic factors in type 1 diabetes. J. Biol. Chem. 277, 43545-43548
37. Banga, J.P. et al. (2004) Modulation of antigen presentation by autoreactive B cell clones specific for GAD65 from a type I diabetic patient. Clin. Exp. Immunol. 135, 74-84
38. Guo, J. et al. (2000) Evidence for antigen presentation to sensitized T cells by thyroid peroxidase (TPO)-specific B cells in mice injected with fibroblasts co-expressing TPO and MHC class II. Clin. Exp. Immunol. 119, 38-46
39. Herold, K.C. et al. (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692-1698
40. Chatenoud, L. (2003) CD3 antibody treatment stimulates the functional capability of regulatory T cells. Novartis Found. Symp. 252, 279-286 (discussion 286-290)
41. Eisenbarth, G.S. et al. (1985) Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res. 2, 271-276
42. Mathieu, C. et al. (2004) Vitamin D and 1,25-dihydroxyvitamin D3 as modulators in the immune system. J. Steroid Biochem. Mol. Biol. 89-90, 449-452
43. Giarratana, N. et al. (2004) A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J. Immunol. 173, 2280-2287
44. Schatz, D. et al. (2004) Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus - a new surrogate measure of non-progression? Pediatr. Diabetes 5, 72-79
45. Raz, I. et al. (2001) Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358, 1749-1753
46. Alleva, D.G. et al. (2002) Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes 51, 2126-2134